These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28889085)

  • 21. Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer.
    Decatris MP; O'Byrne KJ
    Future Oncol; 2016 Aug; 12(15):1805-22. PubMed ID: 27267211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer].
    Miyauchi E; Inoue A
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):666-71. PubMed ID: 27306803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Therapy in Non-Small Cell Lung Cancer.
    Marrone KA; Brahmer JR
    Cancer J; 2016; 22(2):81-91. PubMed ID: 27111902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
    Leventakos K; Mansfield AS
    BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents.
    Meoni G; Cecere FL; Lucherini E; Di Costanzo F
    J Geriatr Oncol; 2013 Jul; 4(3):282-90. PubMed ID: 24070465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers for Immunotherapy.
    Bustamante-Alvarez JG; Owen DH
    Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunotherapy and multidisciplinary approach to treatment in lung cancer].
    Karadurmuş N; Kaya A; Göksel T; Yılmaz Ü; Tülek N
    Tuberk Toraks; 2020 Mar; 68(1):66-75. PubMed ID: 32718141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
    Monteiro ID; Califano R; Mountzios G; de Mello RA
    Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint modulation for non-small cell lung cancer.
    Soria JC; Marabelle A; Brahmer JR; Gettinger S
    Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy comes of age: Immune aging & checkpoint inhibitors.
    Elias R; Karantanos T; Sira E; Hartshorn KL
    J Geriatr Oncol; 2017 May; 8(3):229-235. PubMed ID: 28223073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune checkpoint inhibitors in elderly patients with lung cancer: evidence from phase 3 trials.
    Wang L; Zhou J; Yu X; Su C
    Curr Opin Oncol; 2024 Jan; 36(1):35-43. PubMed ID: 37975311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC.
    Champiat S; Ileana E; Giaccone G; Besse B; Mountzios G; Eggermont A; Soria JC
    J Thorac Oncol; 2014 Feb; 9(2):144-53. PubMed ID: 24419410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
    Wang H; Yu X; Fan Y
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):427-432. PubMed ID: 28641702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
    Camidge DR; Doebele RC; Kerr KM
    Nat Rev Clin Oncol; 2019 Jun; 16(6):341-355. PubMed ID: 30718843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
    Naltet C; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3014-3028. PubMed ID: 34295694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.